---
title: "Nuclear-transport–targeting peptides (SN50 family) as broad anti-inflammatory agents"
id: "frontiers-in-immunology-17-targeting-the-nuclear-gateway-a-new-class-of-cell-penetrating-peptides-for"
canonical_url: "https://medichelpline.com/clinical-feed/frontiers-in-immunology-17-targeting-the-nuclear-gateway-a-new-class-of-cell-penetrating-peptides-for"
content_type: "clinical_feed_article"
specialty: "Infectious Disease"
source_name: "Frontiers in Immunology"
source_url: "https://www.frontiersin.org/articles/10.3389/fimmu.2026.1962554"
published_at: "2026-11-16T00:00:00.000Z"
evidence_level: "Journal Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# Nuclear-transport–targeting peptides (SN50 family) as broad anti-inflammatory agents
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/frontiers-in-immunology-17-targeting-the-nuclear-gateway-a-new-class-of-cell-penetrating-peptides-for
- **Specialty:** [Infectious Disease](https://medichelpline.com/clinical-feed/infectious-disease.md)
- **Primary Source:** Frontiers in Immunology
- **Source URL:** [Original Journal Publication](https://www.frontiersin.org/articles/10.3389/fimmu.2026.1962554)
- **Published At:** 2026-11-16T00:00:00.000Z
- **Evidence Rating:** Journal Feed
## Executive GIST (TL;DR)
- The review describes a novel class of cell-penetrating peptides called **NTCI** (Nuclear Transport Checkpoint Inhibitors) designed to block nuclear import of transcription factors by targeting nuclear transport adaptors. - Prototypical peptide **SN50** and more active congeners **cSN50** and **cSN50.1** contain a cell-penetrating module and a nuclear localization signal (NLS)-mimetic module; they cross membranes directly without engaging cell-surface receptors. - Investigators reported that these peptides lock onto importins (karyopherins), notably **importin α5** and importin β1, imposing a nuclear transport blockade that suppresses transcriptional responses to proinflammatory, metabolic, apoptotic, and oncogenic signaling. - Preclinical data summarized in the review show efficacy across models: polymicrobial **sepsis**, LPS endotoxic shock, alcoholic liver injury, traumatic brain injury, type 1 and type 2 diabetes models, atherosclerosis and fatty liver, autoimmune and allergic disease models, disseminated intravascular coagulation, and oncologic models. - In polymicrobial sepsis models, addition of **cSN50.1** to antibiotics increased survival markedly and reduced activation of thousands of genes in lungs, spleen, and kidneys while simultaneously decreasing cytokine storm mediators and lowering CTLA-4 expression in spleen. - In metabolic models, the **cSN50.1** peptide inhibited metabolic transcription factors (SREBP1/2) and reduced hyperlipidemia, hyperglycemia, fatty liver, and coronary atherosclerosis; the peptide also suppressed genes such as HMG-CoA reductase. - In a type 1 diabetes model, short-course intense treatment with **cSN50.1** reportedly eliminated the need for insulin for one year of observation by extinguishing autoreactive lymphocytes. - The review details the peptide design rationale, avoiding non-human translocators (e.g., HIV Tat, Antennapedia) because of immune-sensitization concerns; one clinical trial with a bacterial-derived hybrid peptide was suspended after immune-sensitization reports. - Authors noted broad genomic suppression in inflammatory states but also described organ-specific differences in regulation (e.g., IL-10 responses in lung vs kidney) and raised the need for clinical trials to test translational value. - The source did not report human clinical trial results for SN50-family peptides; specific dosing regimens and safety data in humans were not provided in the review.
## Clinical Analysis & Structured Key Points
Frontiers | Targeting the nuclear gateway: a new class of cell-penetrating peptides for treatment of inflammation, apoptosis, metabolism, fibrosis, neurodegeneration, and carcinogenesis REVIEW article Front. Immunol. , 16 November 2026 Sec. Inflammation Volume 17 - 2026 | https://doi.org/10.3389/fimmu.2026.1962554 Published in Frontiers in Immunology Inflammation 7 impact factor 11.3 citescore Editor & Reviewers Edited by P P Praveen Papareddy Reviewed by F G Fangyue Guo P L Paola Leonor García-Coronado S J SANTIAGO-JIMÉNEZ JC Outline Figures and Tables Figure 1 View in article Figure 2 View in article Figure 3 View in article Figure 4 View in article Table 1 The SN50 peptide studies in preclinical models of inflammatory diseases. View in article REVIEW article Front. Immunol. , 16 November 2026 Sec. Inflammation Volume 17 - 2026 | https://doi.org/10.3389/fimmu.2026.1962554 Targeting the nuclear gateway: a new class of cell-penetrating peptides for treatment of inflammation, apoptosis, metabolism, fibrosis, neurodegeneration, and carcinogenesis J H Jacek Hawiger 1,2,3 † * J Z Jozef Zienkiewicz 4 1. Department of Medicine, Division of Allergy, Pulmonary and Critical Care Medicine, Vanderbilt University School of Medicine, Nashville, TN, United States 2. Department of Molecular Physiology and Biophysics, Vanderbilt University School of Medicine, Nashville, TN, United States 3. Department of Veterans Affairs, Tennessee Valey Health Care System, Nashville, TN, United States 4. KaMoZo Biologics, Inc., Nashville, TN, United States See more Article metrics View details Abstract Many human diseases mediated by inflammation, allergy, autoimmunity, metabolic dysfunction, degeneration, apoptosis, fibrosis, and malignancy await new treatments. The cellular responses in these diseases depend on signal transduction and gene transcription. On average, one human cell displays 2, 000 proteins with distinct structural and functional characteristics. Cell-penetrating peptides, termed Nuclear Transport Checkpoint Inhibitors (NTCIs), were developed to analyze and control the nuclear transport of these intracellular proteins during inflammatory and metabolic responses. The NTCI peptides comprise two parts: the cell-penetrating module and the intracellular target recognition module. The prototypical cell-penetrating peptide named SN50, and its more active congeners, cSN50 and cSN50.1, cross directly the cell membrane phospholipid bilayer bypassing membrane receptors and transporters. Once inside the cell, the NTCI peptides lock in on their targets, the nuclear transport adaptors termed importins, aka karyopherins, that operate the nuclear gateway. The imposed nuclear transport blockade stops the genomic response to proinflammatory, metabolic, proapoptotic, prooncogenic, and neurodegenerative signaling and subsequent gene transcription in the cell’s nucleus. The cell-penetrating NTCI peptides were tested in isolated human and animal cells as well as in the preclinical models of human diseases. Among them, sepsis, the life-threatening stage of out-of-control infections that afflict annually est. 14 million patients world-wide with 11 million deaths, was controlled by the single cell-penetrating cSN50.1 peptide combined with anti-microbial agent in the preclinical model. The survival of antibiotic treated animals almost doubled. Such a gain in survival due to cSN50.1 peptide treatment was linked to the suppression of thousands of genes in the lungs and kidneys, the sites of acute respiratory distress syndrome (ARDS) and the acute kidney failure (AKI), respectively. Other difficult to treat diseases were also controlled by the cell-penetrating SN50 peptide in preclinical studies. They included: (i) life-threatening liver injury in endotoxic shock and alcoholic intoxication, (ii) traumatic brain injury and other neurologic disorders, (iii) Type 1(juvenile) diabetes, wherein the need for insulin therapy was eliminated for an entire year after intense short-term therapy with the cSN50.1 peptide, (iv) Type 2diabetes and other signs of metabolic dysfunction (the weight gain, hyperlipidemia, fatty liver, and coronary atherosclerosis), which were suppressed after the8-week therapy with the cSN50.1 peptide, (v) autoinflammatory diseases affecting skin and bones, (vi) rheumatoid arthritis and other diseases of the joints,(vii) allergic inflammation-mediated diseases (atopic dermatitis, asthma, another manifestations of the “atopic march”), (viii) Disseminated Intravascular Coagulation, and (ix) hematologic and solid organs oncogenic diseases. Introduction In this review, we address the problem of inflammation mediated diseases and their innovative treatment with a new class of the cell penetrating peptides. These peptides control proinflammatory signaling to the nucleus during the allergic, autoimmune, microbial, metabolic, and profibrotic challenges (see Figure 1 ). Hence, we present the origin, design, and development of these peptides that were proven effective in a wide range of preclinical studies conducted by us and other researchers. Their results indicate the translational value of the cell penetrating peptides and the need for clinical trials in inflammatory diseases caused by allergy, autoimmunity, infections, metabolic dysfunction, fibrosis, neurodegeneration, and carcinogenesis.). The nuclear gateway leads to a broad genomic response in acute and chronic human diseases mediated by inflammation, metabolism, carcinogenesis, neurodegeneration, trauma, and fibrosis Inflammation mediates several human diseases of cardiovascular, pulmonary, renal, hepatobiliary, gastrointestinal, central and peripheral nervous systems as well as the musculoskeletal systems. These diseases are caused by allergic, autoimmune, metabolic, microbial, procoagulant, cytotoxic, and other triggers ( 1 ). In response to these “insults”, recognized by the extracellular or intracellular “sensors” comprising mostly innate immunity receptors and their procoagulant and metabolic counterparts, the nuclear gateway is opened for the transcription factors. Their translocation to the nucleus via the nuclear gateway leads to a broad genomic response in the endothelial cells, adjoining vascular smooth muscle cells, nucleated blood cells, organ-based mononuclear phagocytes, astrocytes, neurons, as well as the epithelial and mesenchymal cells. Therein, the signal transduction and gene transcription culminate in a broad genomic reprograming ( 2 ). Hundreds of genes are activated during inflammatory response. These activated genes encode cytokines (e.g. IL-1 beta, IL-4, IL-6, IL-13, and TNF alpha), chemokines (e.g. IL-8, RANTES), angiogenic growth factors (e.g. Vascular Endothelial Growth Factor, VEGF), procoagulants (e.g. Tissue Factor), cell-adhesion molecules (e.g. vascular cell adhesion molecule-1), signal transducers (e.g. COX2), and metabolic intermediates (e.g. HMG CoA reductase). The products of these activated genes mediate the inflammatory process ( 1 , 2 ). The current countermeasures for inflammation-mediated diseases are limited by their mechanism of action. For example, Aspirin and other non-steroidal anti-inflammatory drugs (NSAID), target one of the proinflammatory signal transducers, the prostaglandin synthase (COX2). In turn, anti-inflammatory glucocorticoids bound to their cognate nuclear receptors display a broad-spectrum activity albeit with adverse metabolic and immunosuppressive side effects. The monoclonal antibodies target single extracellular inflammatory mediators, such as TNF alpha and IL-1 beta or their cognate receptors ( 1 , 3 , 4 ). However, as stated above, the hundreds of genes are activated during the inflammatory response. The products of activated genes mediate the inflammatory process ( 1 , 2 ). Among the cytokines, IL-10 plays multiple roles in inflammatory, autoimmune, and oncogenic responses ( 5 ). This recent structural biology study of the quantum model of human IL-10 protein identified the regions involved in its binding to IL-10 receptor. In turn, the regulation of IL-10 gene expression by the NTCI peptide is dependent on the specific organ responding to the microbial agents. In the lipopolysaccharide (LPS)-induced endotoxic shock model, the cSN50.1 peptide treatment reduced plasma levels of 23 cytokines, chemokines, and hemopoietic growth factors whereas the IL-10 was strikingly elevated) ( 6 ). The subsequent analysis of inflammatory cytokines and chemokines response at the protein level in blood coupled to the organ-based genomic analysis in lungs and kidneys in polymicrobial sepsis model showed differences in the response of IL-10 gene regulated by the cSN50.1 peptide ( 7 ). The development of the SN50 peptide, its congeners, and their translational evolution The initial objective in the studies on controlling inflammation was to impede the nuclear translocation of the transcription factor, nuclear factor kappa B (NF-κB), identified by David Baltimore and his Team ( 8 , 9 ) as immune transactivator. Hence, to target the nuclear transport of the NF-κB and to determine its role in the inflammatory response, the first cell-penetrating NTCI peptide, SN50, was developed ( 10 ). This fragment-designed peptide comprised the nuclear localization signal (NLS) as a nuclear “zip code”, mimicking the sequence displayed by the NF-κB1. To deliver the NLS peptide fragment to the cell interior, the “leading edge” was designed by using the signal sequence hydrophobic region derived from the human Fibroblast Growth Factor 4 (FGF4) ( 11 , 12 ) as a “cell membrane translocator”. Other known “translocators” derived from non-human proteins for intracellular delivery were intentionally avoided. They represent either the cell-penetrating fragments of the Tat protein of the human immunodeficiency virus or the Antennapedia protein of Drosophila melanogaster (the fruit fly), among others ( 11 ). The potential risk of immune sensitization by the repeated applications of those heterogenous “hybrid peptides” in animal studies and future human clinical trials was of concern. Indeed, the report published by others, who substituted the hydrophobic region of the signal sequence of human FGF4 (introduced by us as outlined above), with the sequence patterned after the bacterial transport protein ( 13 ) unfortunately proved our concern. The bacterial-human hybrid peptide was tested in human volunteers, and the clinical trial was abruptly suspended ( 14 ). The first member of the new class of cell-penetrating peptides was termed SN50 (S standing for “signal”, N representing “nuclear” localization sequence derived from NF-κB1, and 50 representing molecular weight of the NF-κB1). The SN50 peptide was enabled to bypass plasma membrane “guideposts”, receptors and transporters, and reach the cytoplasm for the control of the nuclear gateway. This nuclear translocation path consists of nuclear transport adaptors, importin α5 (aka karyopherin α1) and importin β1(aka karyopherin β1), among other nuclear transport proteins. The SN50 peptide selectively targeted the NLS binding pocket in the nuclear transport shuttle, importin α5 ( 15 ). Therefore, the SN50 peptide dismantled the recognition function of importin α5 toward the NF-κB transcription factor family members. Unexpectedly, the SN50 peptide exceeded this objective. It impeded not only the nuclear translocation of the NF-κB family members but also other proinflammatory transcription factors, the cFos/cJun heterodimer, STAT1, and NFATs ( 16 ). As these proinflammatory Stress-Responsive Transcription Factors (SRTFS) are the main regulators of the gene encoding interleukin 2 (lL-2), its expression was suppressed by the SN50 peptide in human T cells ( 16 ). IL-2 is the key immunoregulatory cytokine for B and T lymphocytes ( 17 ), and the inducer of microvascular endothelial permeability responsible for organ edema ( 18 ). The suppression of IL2 gene expression heralded the immunoregulatory function of the SN50 peptide and its congeners through targeting the nuclear gateway. Upon learning that the inflammatory mediators, Interleukin (IL)-6, IL-8, and MCP-1, are involved in the atherosclerosis process ( 19 ), the new hypothesis was tested that the cSN50.1 peptide, more soluble and active cell-penetrating congener, controls atherosclerosis in the preclinical model of hyperlipidemia due to LDL receptor deficiency. Surprisingly, the cSN50.1 peptide, reduced the elevated levels of cholesterol, triglycerides, and glucose in blood of the LDL receptor- deficient mice fed the High Fat Diet! Concurently, their atherosclerotic lesions in the coronary blood vessels were suppressed along with prevention of the fatty liver ( 20 ). This dramatic suppression of coronary atherosclerosis and the metabolic dysfunction-associated steatohepatitis (MASH), was an unexpected outcome of the cSN50.1 peptide’s action in controlling of the proinflammatory cytokines. An alternative mechanism must have been at play and the LDL receptor signaling pathway was considered. This pathway underlies coronary atherosclerosis and elevated blood metabolic biomarkers as delineated by Michael Brown and Joseph Golsdstein with their Team ( 21 ). The key transcriptional players in this process are the Sterol Regulatory Element Binding Proteins (SREBP 1 and 2), the metabolic transcription factors activated in hyperlipidemia ( 22 ). Surprisingly, the cSN50.1, peptide, also inhibited SREBP 1 and 2 in the nuclear gateway. However, these essential metabolic transcription factors do not display NLS that is recognized by the nuclear transport “checkpoint” staffed by Importin α5 (see above). Instead, the metabolic transcription factors display the basic-loop-helix leucine zipper motif, their “address” for nuclear translocation. This motif is recognized by importin/karyopherin beta 1, another nuclear transport “checkpoint” ( 1 ). In contrast, importin/karyopherin alpha 5 recognizes the NLS motif displayed by at least 8 proinflammatory and oxidant transcription factors, NF-κB family, cFos/cJun heterodimer, STAT1, STAT3, NFATs and NRF2. Thus, the two functionally distinct families of transcription factors, proinflammatory (e.g. NF-κB) and metabolic (e.g. SREBP), are effectively targeted by the SN50 peptide and its congeners. The broad control of the nuclear gateway by the single NTCI peptide explains its enormous impact on the genome’s response to polymicrobial sepsis, the life-threatening end stage of out-of-control infections. Indeed, the cSN50.1 peptide suppressed activation and expression of the thousands of genes responding to polymicrobial sepsis in the lungs, spleen, and kidneys ( 7 ). Notably, among these sepsis-induced genes in the spleen (the major blood-filtering immune organ), the cSN50.1 peptide reduced 5-fold the expression of the gene encoding the CTLA-4 receptor, which is responsible for immunosuppression in sepsis and cancer. Hence, the reduction of the immunosuppressive action of CTLA-4 receptor by the cSN50.1 peptide led to the 9-fold increase of anti-bacterial immunity in the spleen, 11-fold increase in the blood, and 12-fold increase in the lungs ( 7 ). The immunoenhancing action of the cSN50.1 peptide was accompanied by its extinguishing of the “cytokine storm” mediated by IL-6, IL-10, TNFα, Interferon γ, and MCP1 in the blood. Consequently, sepsis survival almost doubled (from 44% to 80%) when the NTCI peptide was added to the antibiotic therapy ( 7 ). As there is no established drug for sepsis, beyond the antimicrobials and supportive measures ( 23 ), the SN50.1 peptide awaits clinical trial. These rather striking results in polymicrobial sepsis parallel those obtained in another model of lethal microbial inflammation, endotoxic shock, induced by the Toll-like receptors’ agonist, bacterial lipopolysaccharide (LPS), also known as endotoxin ( 6 ). Therein, 23 out of 26 proinflammatory cytokines and chemokines in the blood, were suppressed by the cSN50.1 peptide while averting inflammatory cells infiltration of the lungs, and controlling the gene encoding Vascular Endothelial Growth Factor (VEGF), that increases the leakiness of small blood vessels contributing to the lung edema. The cSN50.1 peptide attenuated this sign of lung inflammation. Moreover, the cSN50.1 peptide controlled an elevated blood erythropoietin, an indicator of hypoxia, observed in a preclinical model of pulmonary Anthrax, the potential bioweapon ( 24 ). The reduction of the elevated level of erythropoietin by the cSN50.1 peptide is also likely to have an anti-thrombotic activity relevant to Polycythemia Vera with attendant thrombosis ( 25 , 26 ). Previously, the cSN50 peptide controlled microvascular thrombosis, known as Disseminated Intravascular Coagulation (DIC), in the acute liver failure and sepsis (see below). In the liver inflammation models, the cSN50 peptide controlled the genomic pathways responsible for cytokines and chemokines production. It suppressed the expression of proapoptotic genes, central to the extensive apoptosis of liver cells, the process underlying the acute liver failure ( 27 ). This control by the NTCI peptide increased survival from 10% to 75% in an Alcoholic Liver Disease (ALD) model while being cytoprotective in cultured liver-derived cells ( 28 , 29 ). In the model of metabolic dysfunction, (previously referred to as metabolic syndrome), the cSN50.1 peptide controlled weight gain, hyperglycemia, hypercholesterolemia, hypertriglyceridemia, coronary atherosclerosis, and fatty liver. Therein, this peptide suppressed several genes encoding the metabolic signaling intermediates, e.g. HMG-CoA reductase, the known target of statins ( 20 ). Statin-associated side effects, e.g. myopathy, pose a significant therapeutic challenge ( 30 ). Hence, the cSN50.1 peptide may offer a potentially safer alternative to statin therapy. In type 1 (“juvenile”) Diabetes model of an autoimmune inflammation, a two-day intense treatment with the cSN50.1 peptide eliminated the need for insulin injections during the entire year of subsequent observation! The NTCI peptide achieved this by extinguishing autoreactive T cells and B cells that destroy insulin-producing islet cells ( 31 ). This extraordinary eradication of type 1 Diabetes raises a prospect for the cSN50.1 peptide to control other autoimmune inflammatory diseases, such as systemic Lupus Erythematosus and Multiple Sclerosis. In an allergic inflammation model of eczema, termed Atopic Dermatitis (AD), the topically applied the cSN50.1 peptide cleared the skin lesions by controlling 15 genes responsible for AD while also suppressing the same genes in the human skin-derived keratinocytes ( 32 , 33 ). In experimental model of Hemolytic Uremic Syndrome induced by Shiga toxins (Stx), the SN50 peptide, reduced leukocyte adhesion to human vascular endothelial cells stimulated with Stx ( 34 ). The SN50 peptide was also tested in several models of neurological and oncologic diseases. In the model of traumatic brain injury (TBI), the SN50 peptide reduced neuronal cell death, behavioral deficits, and the expression of TNF alpha, cathepsin B, and cytochrome c release ( 35 ). In the models of neurodegenerative disorders, such as the Alzheimer Disease, the SN50 peptide protected the cortical neurons from Amyloid beta toxicity ( 36 , 37 ). In leukemia and T cell lymphoma models, the SN50 peptide dramatically reduced resistance to arsenic trioxide (As203) and strongly enhanced Fas-mediated CH11-induced apoptosis of resistant T- cell Lymphoma variants ( 38 ). In neoplastic diseases of the brain and stomach, the SN50 peptide, alone or in combination with other inhibitors, suppressed the growth of cancer cells ( 39 , 40 ). Table 1 presents the roster of the preclinical studies of the diseases models treated with the prototypical SN50 peptide as reported in over 200 publications. Below, we discuss some of these studies, also including those that were usin
## Related Clinical Research

- [SGLT2 Inhibitors and Rheumatoid Arthritis Risk in Type 2 Diabetes: Summary of Reported Emulated Ta](https://medichelpline.com/clinical-feed/frontiers-in-immunology-19-the-association-between-sglt2-inhibitors-and-rheumatoid-arthritis-risk-in-type.md)
- [Bupropion Hydrochloride for Improving Recovery in Acute Ischaemic Stroke: BASE Trial Protocol](https://medichelpline.com/clinical-feed/bmj-open-4-protocol-for-base-a-multicentre-double-blind-randomised-controlled-trial-of.md)
- [U.S. POINTER: Structured lifestyle program slows brain aging and cardiometabolic risk over 24 mont](https://medichelpline.com/clinical-feed/medical-news-today-0-combining-physical-mental-and-social-habits-slows-brain-aging-in-2-year-trial.md)
- [Later bedtimes and late eating tied to higher metabolic syndrome risk](https://medichelpline.com/clinical-feed/medical-news-today-0-eating-and-sleeping-later-associated-with-increased-health-risks.md)
- [Undiagnosed type 2 diabetes presenting as DKA with hypertriglyceridemia-induced acute pancreatitis](https://medichelpline.com/clinical-feed/cmaj-1-undiagnosed-type-2-diabetes-presenting-as-diabetic-ketoacidosis-with.md)

## Navigation
- [← Back to Infectious Disease Feed](https://medichelpline.com/clinical-feed/infectious-disease.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.